Core Viewpoint - The strategic investment actions by Jinbo Biotechnology have attracted significant attention, particularly due to the involvement of Zhong Shanshan, China's richest man, who is investing a total of 34.03 billion yuan through his companies [1][2]. Group 1: Investment Details - Jinbo Biotechnology will issue shares to Yangshengtang Co., Ltd., representing 6.24% of its total shares before the issuance, with a financing amount not exceeding 2 billion yuan [2]. - The share transfer agreement between Jinbo's controlling shareholder Yang Xia and Hangzhou Jiushi involves the transfer of 5,753,267 shares at a price of 243.84 yuan per share, totaling 1.403 billion yuan [2][3]. - After the transfer, Yang Xia will hold 50.73% of Jinbo, while Hangzhou Jiushi and Yangshengtang will hold 4.71% and 5.87%, respectively, making Zhong Shanshan the second-largest shareholder of Jinbo with 10.58% ownership [3]. Group 2: Company Overview - Jinbo Biotechnology focuses on the research, development, production, and sales of high-end implantable medical devices made from recombinant human collagen, primarily used in aesthetic medicine and skin repair [4]. - The company achieved significant revenue growth, with sales increasing from 233 million yuan in 2021 to 1.443 billion yuan in 2024, and net profit rising from 57.39 million yuan to 732 million yuan during the same period, reflecting a year-on-year growth rate of over 79% [4]. Group 3: Market Potential - The collaboration between Jinbo and Yangshengtang is expected to leverage their respective strengths in large-scale industrial production and market channel development, addressing the urgent need for a comprehensive production and sales system [5]. - The market for collagen-based skin care products is projected to surpass that of hyaluronic acid by 2026, with the overall market size for collagen in China expected to reach 173.8 billion yuan by 2027, of which recombinant collagen products will account for 1.083 billion yuan, representing 62.3% of the market [5].
逾30亿元投资锦波生物，钟睒睒布局千亿重组胶原蛋白市场